Reply to Carl J. Rossi's Comment on “Proton beam and prostate cancer: An evolving debate” by Anthony Zietman [Rep. Pract. Oncol. Radiother. 2013;18:338–42]  by Zietman, Anthony
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) 344
Available  online  at  www.sciencedirect.com
ScienceDirect
jo ur nal home p ag e: ht tp : / /www.e lsev ier .com/ locate / rpor
Reply  to  Carl  J. Rossi’s  Comment  on  “Proton  beam
and prostate  cancer:  An  evolving  debate”  by
Anthony Zietman  [Rep.  Pract.  Oncol.  Radiother.
2013;18:338–42]Anthony Zietman ∗
Department of Radiation Oncology, Massachusetts General Hospital, Fruit Street, Boston, MA  02114, USA
r
[1
evolving debate” by Anthony Zietman [Rep Pract Oncol
Radiother, in press]. Rep Pract Oncol Radiother 2013;18:343.This letter1 makes several thoughtful comments about the
complex history of proton bean development in the USA. It
is indeed true that money is not the only driver and technical
limitations, particularly ﬁeld size, were also a factor. Having
said that, there are plenty of other smaller tumors on which
efforts in PBT could have been concentrated. The conjunction
of the “PSA Revolution” with its rising tide of new prostate
cases and the rise of PBT inevitably brought the two together.
IMRT  was never “held to account” for its rapid expansion
and the cost consequences have been enormous. While I do
believe that an RCT should have been performed for at least
one disease site as proof of principle it simply hasn’t hap-
pened. The history of US health policy does not make one
optimistic that a trial will happen now. CMS  and other major
US insurers are much more  wary  of making the same mis-
take again and, fairly or unfairly, PBT will be held to a higher
standard.
The RBE is certainly around 1.1 and the fact that there was
no excess of grade 3 toxicity in PROG 9509 would seem to sup-
port that except that 60% of the dose in this trial was given
with photons. A subsequent trial giving 82 Gy use proton beam
monotherapy hit, in our opinion, upon a dose limit.2 Photons
have been used to deliver even higher doses successfully and
this does reopen the RBE question. At ultra-high doses small
uncertainties in RBE may matter profoundly.
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http://dx.doi.org/10.1016/j.rpor.2013.10.005Thankfully we  do have the new randomized trial compar-
ing IMRT and PBT as monotherapies which is accruing well.
The trial does allow, and is stratiﬁed for, scanned beam tech-
nology in the proton arm and so we will indeed be comparing
the best with the best.
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